These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7341636)

  • 21. The pharmacology of Parkinson's disease: basic aspects and recent advances.
    Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
    Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Some factors influencing the metabolism of benzylamine by type A and B monoamine oxidase in rat heart and liver.
    Parkinson D; Lyles GA; Browne BJ; Callingham BA
    J Pharm Pharmacol; 1980 Dec; 32(12):844-50. PubMed ID: 6110749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pyridoxal 5'-phosphate levels in brain after treatments which impair cerebral glucose metabolism.
    Wong KL; Tyce GM
    Neurochem Res; 1979 Dec; 4(6):821-6. PubMed ID: 44547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of monoamine oxidase selectively in brain monoamine nerves using the bioprecursor (E)-beta-fluoromethylene-m-tyrosine (MDL 72394), a substrate for aromatic L-amino acid decarboxylase.
    Palfreyman MG; McDonald IA; Fozard JR; Mely Y; Sleight AJ; Zreika M; Wagner J; Bey P; Lewis PJ
    J Neurochem; 1985 Dec; 45(6):1850-60. PubMed ID: 3840523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues.
    Celada P; Artigas F
    J Neurochem; 1993 Dec; 61(6):2191-8. PubMed ID: 7504085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
    Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW
    Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Properties of monoamine oxidase in monkey heart.
    Katayama M; Kobayashi S; Oguchi K; Yasuhara H
    Jpn J Pharmacol; 1984 Aug; 35(4):425-31. PubMed ID: 6438377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Changes in kinetics of deaminated biogenic amines in spontaneous hypertension].
    Ioffina DI; Smirnov IE; Gorkin VZ
    Vopr Med Khim; 1991; 37(1):59-63. PubMed ID: 1858344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
    Wachtel SR; Abercrombie ED
    J Neurochem; 1994 Jul; 63(1):108-17. PubMed ID: 8207420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histochemical characterization of monoamine oxidase in ependyma of rat hypothalamus.
    Williams D; Gascoigne JE; Street M; Williams ED
    Histochem J; 1979 Jan; 11(1):83-95. PubMed ID: 429200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of MAO-A and MAO-B selective inhibitors Ro 41-1049 and Ro 19-6327 on the deamination of newly formed dopamine in the rat kidney.
    Fernandes MH; Soares-da-Silva P
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1309-13. PubMed ID: 2124622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms involved in the prolactin-releasing effect of benserazide.
    Parati EA; Penalva A; Bondiolotti GP; Parenti M; Locatelli V; Picotti GB; Cocchi D; Müller EE
    Eur J Pharmacol; 1984 Jun; 101(3-4):215-21. PubMed ID: 6468496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MAO activity in rat brain stem and cerebral cortex following acute and chronic treatment with L-dopa and ethanol + L-dopa.
    Renis M; Giovine A; Bertolino A
    Pharmacology; 1977; 15(5):392-9. PubMed ID: 918143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modification of L-DOPA pharmacological activity by MAO inhibitors.
    Finberg JP; Sader-Mazbar O
    J Neural Transm (Vienna); 2007; 114(6):801-5. PubMed ID: 17417741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
    Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats.
    Kato T; Dong B; Ishii K; Kinemuchi H
    J Neurochem; 1986 Apr; 46(4):1277-82. PubMed ID: 2419508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain.
    Fowler CJ; Tipton KF
    J Neurochem; 1982 Mar; 38(3):733-6. PubMed ID: 7057191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
    Shen H; Kannari K; Yamato H; Arai A; Matsunaga M
    Tohoku J Exp Med; 2003 Mar; 199(3):149-59. PubMed ID: 12703659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of monoamine oxidase and semicarbazide-sensitive amine oxidase by mexiletine and related compounds.
    Eriksson M; Fowler CJ
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Oct; 327(4):273-8. PubMed ID: 6514011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.